Data as of Jan 29
| +0.19 / +3.14%|
The 3 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +44.00% increase from the last price of 6.25.
The current consensus among 4 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.